Kong Chengying
Title: Associate Chief Physician
I graduated from Tianjin Medical University in July 2011 with a Master of Medicine degree after completing a seven-year clinical medicine program. Upon graduation, I began working in clinical practice, teaching, and research at the Fourth Affiliated Hospital of Zhejiang University. During this time, I completed my standardized residency training at the First Affiliated Hospital of Zhejiang University and my PCCM specialty training at Zhejiang University Sir Run Run Shaw Hospital. I have extensive clinical experience in common, rare, and complex respiratory diseases, as well as critical and life-threatening conditions, and am proficient in diagnostic and therapeutic procedures involving bronchoscopy and ultrasound bronchoscopy. I have been deeply involved in multiple clinical trials of innovative lung cancer drugs within our team. Among these, the interim results of the “Clinical Study of Liposomal mRNA IL-2 Combined with Immune Checkpoint Antibodies for the Treatment of Patients with Advanced Lung Cancer” were presented at the World Lung Cancer Congress held September 6–11, 2024. Current findings indicate that this treatment regimen achieves an 80% response rate, significantly outperforming current standard-of-care regimens and offering a new approach to lung cancer immunotherapy. I specialize in the comprehensive management of lung cancer patients and novel anticancer therapies, including targeted and immunotherapy.